Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
NDTV
Dr Reddy has launched a generic version of Par Pharmaceuticals' Vasostrict in the US market after getting approval from the US Food and Drug Administration (USFDA).
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
The company has launched the product, a generic version of Par Pharmaceuticals' Vasostrict, in the US market after getting approval from the US Food and Drug Administration (USFDA).
"We are pleased to provide this important authorised generic product to patients, especially in these difficult times of COVID-19," Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
